The shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded with a loss of -1.01 points or -1.6% in the most recent session. The shares last traded at $62.16. As per the trading info, the shares saw $12.28 million in upticks and lost $9.79 million in downticks, resulting in a net money flow of $2.49 million. The up/down ratio for the day was measured at 1.25. For the week, the shares had posted -11.45%.From the block trade data available, the total upticks were valued at $3.12 million and the total downticks were valued at $0.62 million, thereby putting the up/down ratio at 5.02. The net money flow for the block transaction was $2.5 million.
Currently the company Insiders own 4% of Alnylam Pharmaceuticals shares according to the proxy statements. Institutional Investors own 83.74% of Alnylam Pharmaceuticals shares. On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (Chief Executive Officer) of Alnylam Pharmaceuticals, Inc., Maraganore John had sold 30,151 shares worth of $2,046,348 in a transaction dated April 19, 2016. In this transaction, 30,151 shares were sold at $67.87 per share.
Alnylam Pharmaceuticals (NASDAQ:ALNY) stock ended Monday session in the red zone in a volatile trading. The stock closed down 2.52 points or 3.99% at $60.65 with 1,182,457 shares getting traded. Post opening the session at $62.54, the shares hit an intraday low of $60.39 and an intraday high of $63.19 and the price was in this range throughout the day. The company has a market cap of $5,189 million and the number of outstanding shares have been calculated to be 85,560,535 shares. The 52-week high of Alnylam Pharmaceuticals (NASDAQ:ALNY) is $140 and the 52-week low is $49.96.
Many analysts have stated their opinion on the company shares. Leerink Swann maintains its view on Alnylam Pharmaceuticals (NASDAQ:ALNY) according to the research report released by the firm to its investors. The shares have now been rated Outperform by the stock experts at the ratings house. Leerink Swann lowers the price target from $120 per share to $107 per share on Alnylam Pharmaceuticals . The rating by the firm was issued on May 3, 2016.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.